This class of drugs was never specifically tested in a defined KRAS mutant NSCLC population, in part due to the recognition that KRAS could be undergo an alternative modification which would allow it to localize to the membrane even in the absence of farnesylation. This evidence concerns the gene KRAS and non-small cell lung carcinoma.